Alnylam Pharmaceuticals, Inc.
ALNY
$304.67
$6.092.04%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.20% | 34.90% | -33.26% | 107.00% | 54.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.20% | 34.90% | -33.26% | 107.00% | 54.82% |
| Cost of Revenue | 7.68% | 19.75% | 1.89% | -19.56% | 20.24% |
| Gross Profit | 22.13% | 38.57% | -37.71% | 153.30% | 62.00% |
| SG&A Expenses | 13.83% | 49.07% | 10.95% | 15.70% | 14.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.13% | 25.57% | 7.67% | 11.42% | 14.64% |
| Operating Income | 141.62% | 9.66% | -135.96% | 121.15% | 71.01% |
| Income Before Tax | 34.58% | -40.87% | -172.09% | 95.93% | 63.11% |
| Income Tax Expenses | 576.45% | -60,315.85% | -2.71% | 215.26% | 35.02% |
| Earnings from Continuing Operations | 12.82% | 39.24% | -175.51% | 93.88% | 62.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.82% | 39.24% | -175.51% | 93.88% | 62.13% |
| EBIT | 141.62% | 9.66% | -135.96% | 121.15% | 71.01% |
| EBITDA | 208.57% | 11.59% | -127.70% | 129.36% | 77.96% |
| EPS Basic | 15.19% | 40.90% | -173.53% | 93.98% | 62.74% |
| Normalized Basic EPS | 37.91% | -36.17% | -162.22% | 96.50% | 63.17% |
| EPS Diluted | 15.19% | 40.90% | -175.53% | 93.98% | 62.74% |
| Normalized Diluted EPS | 37.91% | -36.17% | -165.27% | 96.50% | 63.17% |
| Average Basic Shares Outstanding | 2.80% | 2.79% | 2.69% | 1.66% | 1.63% |
| Average Diluted Shares Outstanding | 2.80% | 2.79% | -2.09% | 1.66% | 1.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |